Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Study of SNG1153 for treating advanced cancer

Trial Profile

A Study of SNG1153 for treating advanced cancer

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SNG-1153 (Primary)
  • Indications Cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Jun 2018 New trial record
    • 22 Jun 2018 According to a Shenogen Pharma media release, Shandong Shenogen Pharmaceutical Co., Ltd. has received the Clinical Trial Approval for SNG1153 in May 2018, issued by the State Food and Drug Administration, with the approval number-2018L02511.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top